Today: 29 April 2026
Browse Category

NASDAQ:ZBIO 22 December 2025 - 6 January 2026

Zenas BioPharma stock slides again premarket after INDIGO Phase 3 data sparks fresh scrutiny

Zenas BioPharma stock slides again premarket after INDIGO Phase 3 data sparks fresh scrutiny

Zenas BioPharma shares dropped 5.8% to $15.66 in premarket trading Tuesday, extending a 52% plunge after Phase 3 data for obexelimab in IgG4-related disease. The drug met its main goal but fell short of results seen with Amgen’s Uplizna, prompting Morgan Stanley to downgrade the stock and cut its price target. Zenas plans to file for FDA approval in Q2 2026.
6 January 2026
··
Zenas BioPharma (ZBIO) stock steadies in premarket after 8% slide as INDIGO trial timing stays in focus

Zenas BioPharma (ZBIO) stock steadies in premarket after 8% slide as INDIGO trial timing stays in focus

Zenas BioPharma shares were unchanged at $39.05 in premarket trading Tuesday after falling 8.1% Monday. The stock is down about 12% from its December 24 high as investors await Phase 3 INDIGO trial results expected around year-end. Monday’s session saw shares dip to $38.96 before closing at $39.05. Technical support is near $37.78, with resistance just above $41.
30 December 2025
·
Zenas BioPharma (ZBIO) Stock Hits a Record High on Dec. 22, 2025 as INDIGO Phase 3 Catalyst Nears — Latest News, Analyst Forecasts, and What’s Next

Zenas BioPharma (ZBIO) Stock Hits a Record High on Dec. 22, 2025 as INDIGO Phase 3 Catalyst Nears — Latest News, Analyst Forecasts, and What’s Next

Zenas BioPharma shares jumped about 14% to $41.23 on December 22, 2025, hitting a record high of $41.67 ahead of expected Phase 3 INDIGO trial results for obexelimab in IgG4-related disease. Citi and Wedbush both reiterated bullish ratings and price targets, citing the upcoming clinical data as a near-term catalyst.
22 December 2025
·

Stock Market Today

  • Shore Capital Reaffirms 'House Stock' Rating for Warpaint London Amid Price Target Cut
    April 29, 2026, 3:30 PM EDT. Warpaint London (LON:W7L) saw its 'house stock' rating reaffirmed by Shore Capital Group on Wednesday, despite Berenberg Bank cutting its price target from GBX 510 to GBX 470 with a 'buy' rating. The stock fell 8.3% to GBX 172 on heavy volume, surpassing its average daily trade. With a market cap near £139 million and a P/E ratio of 8.7, Warpaint London posted Q1 earnings of GBX 16.68 per share and a return on equity of 21.3%. The company operates in cosmetics under brands like W7 and Technic, selling internationally. Analysts maintain an average consensus rating of 'Buy' with a target around GBX 455. Investors watched closely as the stock traded below its 50-day average of GBX 215.58 amid mixed analyst signals.

Latest article

Marathon Petroleum Stock Jumps Before Earnings as Refining Margins Put Wall Street on Alert

Marathon Petroleum Stock Jumps Before Earnings as Refining Margins Put Wall Street on Alert

29 April 2026
Marathon Petroleum shares rose 3.2% to $240.05 Wednesday as investors anticipated its May 5 earnings report, following a surge in fuel margins during the first quarter. Phillips 66 and Valero also gained after posting stronger-than-expected results. Marathon’s Robinson refinery in Illinois began planned maintenance in March. U.S. gasoline prices hit $4.18 a gallon, the highest since 2022, according to AAA.
Why MaxLinear Stock Is Surging as AI Data-Center Demand Rewrites the Story

Why MaxLinear Stock Is Surging as AI Data-Center Demand Rewrites the Story

29 April 2026
MaxLinear shares rose about 34% to $69.58 on Wednesday after Loop Capital upgraded the stock and raised its target to $75. The surge followed a first-quarter report showing infrastructure revenue up 136% to become the company’s largest segment. Total revenue climbed 43% to $137.2 million. MaxLinear guided second-quarter revenue to $160–$170 million, citing strong demand for data-center optical products.
FuelCell Energy Stock Jumps As AI Power Bet Gets Fresh Boost From Bloom Energy

FuelCell Energy Stock Jumps As AI Power Bet Gets Fresh Boost From Bloom Energy

29 April 2026
FuelCell Energy shares climbed $2.75 to $12.69 Wednesday, trading on heavy volume after Bloom Energy raised its 2026 outlook and reported a 130% jump in first-quarter revenue to $751.1 million. Bloom shares surged over 23% after announcing its fuel cells would power Oracle’s planned New Mexico AI data center. FuelCell’s first-quarter revenue rose 61% to $30.5 million, but it posted a $23.7 million net loss.
Go toTop